1. Home
  2. HYPR vs LUNG Comparison

HYPR vs LUNG Comparison

Compare HYPR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

N/A

Current Price

$0.67

Market Cap

82.4M

Sector

Health Care

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$2.68

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYPR
LUNG
Founded
2014
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4M
97.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
HYPR
LUNG
Price
$0.67
$2.68
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
$2.03
★ $3.70
AVG Volume (30 Days)
893.1K
★ 993.2K
Earning Date
11-09-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.21
7.64
EPS
★ N/A
N/A
Revenue
$13,563,000.00
★ $90,497,000.00
Revenue This Year
$49.18
$0.33
Revenue Next Year
$29.74
$8.68
P/E Ratio
N/A
★ N/A
Revenue Growth
5.22
★ 8.01
52 Week Low
$0.70
$1.13
52 Week High
$1.94
$3.25

Technical Indicators

Market Signals
Indicator
HYPR
LUNG
Relative Strength Index (RSI) 37.20 64.05
Support Level $0.70 $1.26
Resistance Level $1.05 N/A
Average True Range (ATR) 0.04 0.24
MACD -0.00 0.11
Stochastic Oscillator 16.71 64.45

Price Performance

Historical Comparison
HYPR
LUNG

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales, which consist of sales from subscriptions of bundled devices, maintenance, and software. The company is in the health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. The Company operates in one business segment, which includes all activities related to production, supply, service, and commercialization of the Swoop system.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: